Core Viewpoint - NLS Pharmaceutics Ltd. has launched a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence, addressing a significant global health crisis related to opioid addiction [1][2][3] Company Overview - NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on developing therapies for rare and complex central nervous system disorders [11] - The company was founded in 2015 and is headquartered in Switzerland, led by an experienced management team with a history of developing and commercializing product candidates [11] Preclinical Program Highlights - The preclinical program aims to assess the safety and efficacy of Mazindol ER in models of fentanyl dependence, with a study expected to be completed within 12-18 months [5][9] - Mazindol ER is designed to provide a non-opioid alternative for treating fentanyl addiction, targeting neurochemical imbalances and supporting recovery through its multimodal action on neurotransmitter systems [4][6] Mechanism of Action - Mazindol ER acts on multiple neurotransmitter pathways, including: - Modulation of 5-HT1A receptors to regulate mood and anxiety [7] - Interaction with mu-opioid receptors to reduce cravings and withdrawal symptoms without reinforcing addiction [8] - Partial agonist activity at orexin-2 receptors to aid in sleep-wake cycle restoration [7][8] Future Outlook - NLS aims to leverage initial findings from the preclinical study to expand research and pursue commercialization opportunities for Mazindol ER in treating fentanyl dependence [11] - The company has secured patents for Mazindol ER, which strengthens its intellectual property position and supports ongoing development [10][14] Merger Information - NLS has filed a Registration Statement with the SEC regarding a proposed merger with Kadimastem, a clinical-stage cell therapy company [11][12] - Following the merger, both companies expect to continue developing NLS's Dual Orexin Agonist platform [12]
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence